Rapid Micro Biosystems to Participate in the Stifel 2024 Healthcare Conference
LEXINGTON, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences...
Pharmaceutical
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials now Active and...
Shanghai thriving as global investment hub
BEIJING, Nov. 7, 2024 /PRNewswire/ -- A news report from chinadaily.com.cn： The 2024 Shanghai City Investment Promotion Conference, held on Nov...
Medexus Announces Strong Fiscal Q2 2025 Results
Fiscal Q2 2025 revenue of $26.3 million, net income of $0.1 million, operating income of $1.6 million, and Adjusted EBITDA*...
Cryoport Reports Third Quarter 2024 Financial Results
Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% year-over-year Supported a record total of...
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Top line results for JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in patients with moderate to severe...
Cellev8 Nutrition Shareholder Update
WELLINGTON, FL / ACCESSWIRE / November 7, 2024 / Dear Valued Shareholders,I am thrilled to share with you some of...
Women Health App Market Surges to USD 8 Billion by 2030, Propelled by 14.4% CAGR – Verified Market Reports®
The women's health app market is driven by the growing awareness of women's health issues, increasing smartphone penetration, and the...
Hospital PMI® at 51.9%; October 2024 Hospital ISM® Report On Business®
TEMPE, Ariz., Nov. 7, 2024 /PRNewswire/ -- Economic activity in the hospital subsector grew in October for the 14th consecutive month...
Health Union Releases 2024 Findings of “In America” and “Patient Experience” Syndicated Healthcare Research, Offering Unmatched Patient Insights
With data from over 37,000 individuals across 50+ conditions, Health Union's 2024 syndicated healthcare research findings provide fresh perspectives on...
Thompson Street Capital Partners Portfolio Company Savillex Acquires Optimum Processing, Inc.
ST. LOUIS, Nov. 7, 2024 /PRNewswire/ -- Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis,...
Waters New Software Delivers Lab-Centric Business Intelligence and Enables Confident Audit-Readiness
News Summary: waters_connect™ Data Intelligence software provides laboratories with comprehensive business intelligence on their chromatographic data throughout the product development...
DarioHealth Reports Third Quarter 2024 Financial and Operating Results
Demonstrated strong improvements in financial performance and business momentum.Q3 revenue of $7.42 million increased 18.7% over Q2 2024 and 111%...
Lexaria Updates Fast-Moving GLP-1 ‘Arm’s Race’ Developments
DehydraTECH™ for GLP-1 being optimized for global pharmaceutical use KELOWNA, BC / ACCESSWIRE / November 7, 2024 / Lexaria Bioscience...
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results
Revenue increased 31% for the quarter compared to same period prior yearPositive cash flows from operations of $0.35 million for...
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company...
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product...
Promising cooperation between medac and chiron for the development of organ-on chip technology
WEDEL, Germany, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Testing new substances in animals is a regulatory cornerstone of drug development....
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024
Financials for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 will be released on Thursday, November 14,...